Reviva Pharmaceuticals Holdings, Inc. Operating Lease, Expense
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Operating Lease, Expense of $16.40 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-12
- Reviva Pharmaceuticals Holdings, Inc. operating lease, expense for the quarter ending 2026-06-30 was $16.40K, a 18.84% increase year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. operating lease, expense for the quarter ending 2026-03-31 was $14.50K, a 5.07% increase year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. operating lease, expense for the quarter ending 2025-12-31 was $14.00K, a 8.12% increase year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. operating lease, expense for the quarter ending 2025-09-30 was $13.80K, a 7.01% increase year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. operating lease, expense for fiscal 2025 was $55.40K, a 10.40% increase from fiscal 2024.
- Reviva Pharmaceuticals Holdings, Inc. operating lease, expense for fiscal 2024 was $50.18K, a 150.90% increase from fiscal 2023.
- Reviva Pharmaceuticals Holdings, Inc. operating lease, expense for fiscal 2023 was $20.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.40K 10-Q · filed 2026-08-12 | $30.90K 10-Q · filed 2026-08-12 | $44.90K derived: sum of 3 quarters · filed 2026-08-12 | $58.70K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $14.50K 10-Q · filed 2026-05-13 | $28.50K derived: sum of 2 quarters · filed 2026-05-13 | $42.30K derived: sum of 3 quarters · filed 2026-05-13 | $56.10K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $27.80K derived: sum of 2 quarters · filed 2026-03-30 | $41.60K derived: sum of 3 quarters · filed 2026-08-12 | $55.40K 10-K · filed 2026-03-30 |
| 2025-09-30 | $13.80K 10-Q · filed 2025-11-13 | $27.60K derived: sum of 2 quarters · filed 2026-08-12 | $41.40K 10-Q · filed 2025-11-13 | $54.35K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $13.80K 10-Q · filed 2026-08-12 | $27.60K 10-Q · filed 2026-08-12 | $40.55K derived: sum of 3 quarters · filed 2026-08-12 | $53.45K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $13.80K 10-Q · filed 2026-05-13 | $26.75K derived: sum of 2 quarters · filed 2026-05-13 | $39.65K derived: sum of 3 quarters · filed 2026-05-13 | $52.74K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $12.95K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $25.84K derived: sum of 2 quarters · filed 2026-03-30 | $38.95K derived: sum of 3 quarters · filed 2026-03-30 | $50.18K 10-K · filed 2026-03-30 |
| 2024-09-30 | $12.90K 10-Q · filed 2025-11-13 | $26.00K derived: sum of 2 quarters · filed 2025-11-13 | $37.23K 10-Q · filed 2025-11-13 | $41.84K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $13.10K 10-Q · filed 2025-08-14 | $24.30K 10-Q · filed 2025-08-14 | $28.95K derived: sum of 3 quarters · filed 2025-08-14 | $34.10K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $11.20K 10-Q · filed 2025-05-15 | $15.85K derived: sum of 2 quarters · filed 2025-05-15 | $21.00K derived: sum of 3 quarters · filed 2025-05-15 | $26.20K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $4.64K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-03 | $9.80K derived: sum of 2 quarters · filed 2025-04-03 | $15.00K derived: sum of 3 quarters · filed 2025-04-03 | $20.00K 10-K · filed 2025-04-03 |
| 2023-09-30 | $5.16K 10-Q · filed 2024-11-14 | $10.36K derived: sum of 2 quarters · filed 2024-11-14 | $15.36K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $5.20K 10-Q · filed 2024-08-14 | $10.20K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $5.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |